Compare AbCellera Biologics Inc (ABCL) vs Marriott International Inc (MAR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Marriott International Inc — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while Marriott International Inc trades at $372.52 (market cap $100.40B). The key difference: Marriott International Inc is far larger — about 42.7× AbCellera Biologics Inc's market cap, and Marriott International Inc pays a 0.77% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | MAR | |
|---|---|---|
Market Cap | $2.35B | $100.40B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $402.54 |
52-Week Low | $2.78 | $255.35 |
Enterprise Value | $1.99B | $117.35B |
Dividend Yield | — | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Marriott International (MAR) trades at $380.75, up 2.09% today, near its consensus price target of $386.42. The stock shows a bullish technical trend with strong moving averages, while fundamentals reveal robust revenue growth to $26.19B in 2025 and a net income margin of 9.72%. Recent developments include a strategic beverage agreement with Coca-Cola and the launch of an AI-powered travel search tool, Ask Bonvoy, enhancing its digital offerings.
The outlook for MAR is positive with analyst consensus leaning bullish (44% Buy ratings), though high debt levels and owner disputes over the Bonvoy loyalty program pose risks. Earnings beats in recent quarters support growth, but valuation metrics like a P/E of 39.76 suggest premium pricing. Investors should weigh solid operational cash flow against escalating liabilities for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →
